NLRP3 and rheumatoid arthritis: Notably, IL-1 has emerged as a critical driver of bone erosion via nucleotide- binding oligomerization domain 3 (NLRP3) inflammasome activation, underscoring its therapeutic potential for refractory RA and structural damage mitigation.